Use of 852A in Metastatic Cutaneous Melanoma.
NCT00189332 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2008-10-27
Summary
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
Conditions
- Melanoma
- Unresectable Metatstatic Cutaneous Melanoma
Interventions
- DRUG
-
852A
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-02-28
- Primary Completion
- 2006-08-31
- Completion
- 2006-08-31
Countries
- France
- Germany
- Switzerland
Study Locations
More Related Trials
-
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
NCT04812470 ·Status: COMPLETED ·Phase: PHASE1
-
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124 ·Status: COMPLETED
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 ·Status: COMPLETED ·Phase: PHASE2
-
RTA 408 Capsules in Patients With Melanoma - REVEAL
NCT02259231 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
NCT00107718 ·Status: COMPLETED ·Phase: PHASE2
-
Intratumoral Injection Of Alpha-Gal Glycosphingolipids
NCT00668512 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
NCT00735332 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
NCT01781572 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
NCT03865212 ·Status: TERMINATED ·Phase: PHASE1
-
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
NCT00095953 ·Status: COMPLETED ·Phase: PHASE2
-
Viral Therapy in Treating Patients With Metastatic Melanoma
NCT00651157 ·Status: COMPLETED ·Phase: PHASE2
-
Intratumoral Administration of L19IL2/L19TNF
NCT02076633 ·Status: COMPLETED ·Phase: PHASE2
-
Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
NCT02101008 ·Status: COMPLETED ·Phase: PHASE2
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
NCT05903937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
NCT02350972 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NCT00963664 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
NCT01886235 ·Status: COMPLETED ·Phase: NA
-
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
NCT00085306 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Use Study for Advanced Melanoma.
NCT00584493 ·Status: NO_LONGER_AVAILABLE
-
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
NCT07280832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dose Escalation Study of MLN4924 in Adults With Melanoma
NCT01011530 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
NCT01308762 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
NCT00521053 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
NCT01522664 ·Status: COMPLETED ·Phase: PHASE1